Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of sacubitril/valsartan in Japanese pediatric heart failure patients after CLCZ696B2319E1
2023-001004-33Phase 4
- Sponsor
- Novartis
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in heart failure (HF) and left ventricular systolic dysfunction (LVSD), sponsored by Novartis. Primary endpoint: Adverse events (AEs).
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2023-001004-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001004-33.